HERO trial: A rescue from injectable androgen deprivation therapy.
作者信息
Ranjan Satish Kumar
机构信息
Department of Urology, AIIMS, Rishikesh, Uttarakhand, India.
出版信息
Indian J Urol. 2021 Apr-Jun;37(2):193-194. doi: 10.4103/iju.IJU_497_20. Epub 2021 Apr 1.
Abstract
摘要
相似文献
1
HERO trial: A rescue from injectable androgen deprivation therapy.HERO试验：从注射用雄激素剥夺治疗中解救出来。
Indian J Urol. 2021 Apr-Jun;37(2):193-194. doi: 10.4103/iju.IJU_497_20. Epub 2021 Apr 1.
2
Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.对于无症状、不可治愈的前列腺癌患者，立即进行与延迟雄激素剥夺治疗相关的生活质量（TROG 03.06 和 VCOG PR 01-03 [TOAD]）：一项随机、多中心、非盲、3 期临床试验。
Lancet Oncol. 2017 Sep;18(9):1192-1201. doi: 10.1016/S1470-2045(17)30426-6. Epub 2017 Jul 28.
3
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.雄激素剥夺治疗时机对 PSA 升高的前列腺癌患者的影响（TROG 03.06 和 VCOG PR 01-03 [TOAD]）：一项随机、多中心、非盲、3 期临床试验。
Lancet Oncol. 2016 Jun;17(6):727-737. doi: 10.1016/S1470-2045(16)00107-8. Epub 2016 May 4.
4
Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.静脉注射唑来膦酸预防接受雄激素剥夺治疗且存在多种骨质流失风险因素的退伍军人骨质疏松症。
J Urol. 2009 Nov;182(5):2257-64. doi: 10.1016/j.juro.2009.07.046. Epub 2009 Sep 16.
5
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.高剂量放疗联合短期或长期雄激素剥夺治疗局限性前列腺癌（DART01/05 GICOR）：一项随机、对照、3 期临床试验。
Lancet Oncol. 2015 Mar;16(3):320-7. doi: 10.1016/S1470-2045(15)70045-8. Epub 2015 Feb 19.
6
Reduced Cardiovascular Capacity and Resting Metabolic Rate in Men with Prostate Cancer Undergoing Androgen Deprivation: A Comprehensive Cross-Sectional Investigation.接受雄激素剥夺治疗的前列腺癌男性心血管能力和静息代谢率降低：一项全面的横断面调查
Adv Urol. 2015;2015:976235. doi: 10.1155/2015/976235. Epub 2015 Oct 26.
7
Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma: A case report.涎腺导管癌中雄激素剥夺治疗耐药的获得：一例报告
Rare Tumors. 2018 Sep 19;10:2036361318798867. doi: 10.1177/2036361318798867. eCollection 2018.
8
Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor.
J Urol. 1993 Apr;149(4):779-82. doi: 10.1016/s0022-5347(17)36206-7.
9
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.靶向转移性激素敏感型前列腺癌：化疗联合激素治疗及新的联合治疗策略
J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117.
10
The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.芬-Prostate 研究 VII：晚期前列腺癌患者间歇性与连续性雄激素剥夺治疗。
J Urol. 2012 Jun;187(6):2074-81. doi: 10.1016/j.juro.2012.01.122. Epub 2012 Apr 11.
引用本文的文献
1
Development of a Novel Patient-Reported Outcome Measure to Assess Symptoms and Impacts of Androgen Deprivation Therapy for Advanced Prostate Cancer.开发一种新的患者报告结局测量工具，用于评估晚期前列腺癌雄激素剥夺治疗的症状和影响。
Adv Ther. 2024 Aug;41(8):3076-3088. doi: 10.1007/s12325-024-02888-9. Epub 2024 Jun 11.
本文引用的文献
1
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.口服瑞戈非尼在晚期前列腺癌中的雄激素剥夺治疗。
N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29.
2
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.口服促性腺激素释放激素受体拮抗剂瑞戈非尼作为局部中危前列腺癌患者外照射放疗的新辅助/辅助雄激素剥夺治疗：一项随机、开放标签、平行组 2 期试验。
Eur Urol. 2020 Aug;78(2):184-192. doi: 10.1016/j.eururo.2020.03.001. Epub 2020 Apr 6.
3
Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.临床局限性前列腺癌：美国临床肿瘤学会对美国泌尿外科学会/美国放射肿瘤学会/泌尿肿瘤学会指南的临床实践指南认可
J Clin Oncol. 2018 Nov 10;36(32):3251-3258. doi: 10.1200/JCO.18.00606. Epub 2018 Sep 5.
4
Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth.雄激素“爆发”风险的饱和模型时代：又一个历史神话。
Eur Urol Focus. 2019 Jan;5(1):81-89. doi: 10.1016/j.euf.2017.06.008. Epub 2017 Jul 1.
5
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.地加瑞克的疗效与安全性：一项针对前列腺癌患者的为期12个月的、比较性、随机、开放标签、平行组III期研究。
BJU Int. 2008 Dec;102(11):1531-8. doi: 10.1111/j.1464-410X.2008.08183.x.
6
The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer.双侧睾丸切除术或口服雌激素治疗转移性前列腺癌后血清睾酮达到去势水平的时间。
Urology. 1994 Jun;43(6):834-7. doi: 10.1016/0090-4295(94)90145-7.
7
Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.前列腺癌患者接受促黄体生成素释放激素激动剂治疗时因疾病发作导致的猝死。
J Urol. 1990 Dec;144(6):1479-80. doi: 10.1016/s0022-5347(17)39774-4.
Zotero 插件